Company news

Entera Bio Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors

October 27, 2026

Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting

October 13, 2026

Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting

October 8, 2026

Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise

October 6, 2026

Correction: Entera to Participate in Upcoming Fall Investor Conferences

August 27, 2026

Entera to Participate in Upcoming Fall Investor Conferences

August 27, 2026

Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation

August 18, 2026

Entera Announces Second Quarter 2026 Financial Results and Business Updates

August 7, 2026

Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting

August 4, 2026

Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

July 31, 2026

Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE

July 28, 2026

Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement

July 27, 2026

America's Osteoporosis Crisis and the Oral Peptide Player You Should Watch (NASDAQ: ENTX)

July 7, 2026

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

June 22, 2026

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

June 16, 2026

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

June 15, 2026

Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation

May 28, 2026

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

May 8, 2026

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

April 14, 2026

Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds

April 1, 2026

Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates

March 26, 2026

Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis

March 4, 2026

Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board

February 27, 2026

Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference

February 25, 2026

Entera Bio Announces Open Market Purchases of Company Stock by Board Members

February 11, 2026

Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones

February 9, 2026

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism

February 4, 2026

Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook

January 21, 2026

Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation

December 23, 2025

Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)

December 22, 2025

Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference

November 18, 2025

Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates

November 14, 2025

Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women

October 23, 2025

Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting

October 16, 2025

Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress

September 15, 2025

Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025

September 8, 2025

Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences

August 28, 2025

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

August 8, 2025

Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis

July 28, 2025

OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress

July 8, 2025

Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting

June 26, 2025

OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting

June 25, 2025

Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

May 9, 2025

Entera Bio’s EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis - Highlighted as Oral Presentation at WCO-IOF ESCEO

April 15, 2025

Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates

March 28, 2025

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

March 17, 2025

Entera Bio to Participate in Upcoming Events

February 24, 2025

EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases

February 19, 2025

Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

January 26, 2025

Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates

November 7, 2024

Older news releases →

Calls

Decks

The 5 newest of 9 decks. Every deck is listed under its year.